Home > Neurology > AAN 2022 > Parkinson’s Disease > Prasinezumab in Parkinson’s disease: delayed-start analysis of PASADENA trial

Prasinezumab in Parkinson’s disease: delayed-start analysis of PASADENA trial

Presented By
Dr Gennaro Pagano, King’s College London, UK
Conference
AAN 2022
Trial
Phase 2, PASADENA
Doi
https://doi.org/10.55788/54b72d2f
An efficacy signal of prasinezumab after 52 weeks in part 1 of the PASADENA study was further evaluated in an exploratory delayed-start analysis of part 2 of PASADENA. In patients with early Parkinson’s disease (PD), the difference in MDS-UPDRS Part III in the early-start versus the delayed-start group persisted after 104 weeks. Prasinezumab is a humanised, monoclonal antibody specifically designed to target α-synucleinopathy (α-Syn) in PD. Prasinezumab demonstrated efficacy in multiple in vivo and cellular α-Syn-models. It has the potential to slow PD progression by protecting neurons from toxic α-Syn species. The effect of prasinezumab was evaluated in the placebo-controlled, phase 2 PASADENA study (NCT03100149). The primary endpoint was the Movement Disorders Society–Unified Parkinson’s disease Rating Scale (MDS-UPDRS) sum of Parts I, I...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on